Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2016 03:00 ET | Source: Karolinska Development AB

Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer

Details from the Aprea announcement follow: “The initiation of the Phase II clinical study marks an important milestone for Aprea,” said Christian S. Schade, President and Chief Executive...
September 30, 2016 03:00 ET | Source: Karolinska Development AB

Ändring av antalet aktier och röster i Karolinska Development

Idag, den sista handelsdagen i månaden, finns totalt 53.464.998 utestående aktier och 66.992.880 röster i Karolinska Development. Av dessa är 1.503.098 aktier av serie A med 15.030.980 röster och...
September 30, 2016 03:00 ET | Source: Karolinska Development AB

Change of number of shares and votes in Karolinska Development

Today, the last trading day of the month, there are in total 53,464,998 shares outstanding which in total have 66,992,880 votes in Karolinska Development. Of these, 1,503,098 are series A...
September 27, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin

Dilafor’s largest existing shareholder, KDev Investments (an investment fund jointly owned by Karolinska Development (Nasdaq Stockholm: KDEV) and Rosetta Capital, also participated in this round. As...
September 20, 2016 03:42 ET | Source: Karolinska Development AB

Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research

Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million people worldwide. Mutations in alpha-synuclein are strongly linked to development of Parkinson’s...
September 05, 2016 02:00 ET | Source: Karolinska Development AB

Stockholm September 5, 2016, Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.

This preliminary data is part of a larger retrospective study which will be published and presented once completed. The preliminary data will be available in the OssDsign booth (#1)...
August 31, 2016 06:06 ET | Source: Karolinska Development AB

Karolinska Development: Interim Report for January-June 2016

Jim Van heusden, CEO, comments: “In the first half of 2016 Karolinska Development achieved three key developments within our portfolio companies: we secured additional financing; ensured continued...
August 31, 2016 06:06 ET | Source: Karolinska Development AB

Karolinska Development: Delårsrapport för januari - juni 2016

Jim Van heusden, CEO, kommenterar: “Under första halvåret 2016 uppnådde Karolinska Development tre viktiga mål tillsammans med portföljbolagen: ytterligare finansiering säkrades, en fortsatt...
August 31, 2016 02:42 ET | Source: Karolinska Development AB

Karolinska Development: Interim Report for January-June 2016

Jim Van heusden, CEO, comments: “In the first half of 2016 Karolinska Development achieved three key developments within our portfolio companies: we secured additional financing; ensured continued...
August 31, 2016 02:42 ET | Source: Karolinska Development AB

Karolinska Development: Delårsrapport för januari - juni 2016

Jim Van heusden, CEO, kommenterar: “Under första halvåret 2016 uppnådde Karolinska Development tre viktiga mål tillsammans med portföljbolagen: ytterligare finansiering säkrades, en fortsatt...